US 11,718,671 B2
Bispecific antibody and uses thereof
Wenjun Zhang, Guangzhou (CN); Cuijuan Chen, Guangzhou (CN); Xuemei Wei, Guangzhou (CN); and Tonghui Luo, Guangzhou (CN)
Assigned to Excelmab, Inc., Guangdong (CN)
Appl. No. 16/965,541
Filed by EXCELMAB INC., Guangzhou (CN)
PCT Filed Jan. 7, 2019, PCT No. PCT/CN2019/070655
§ 371(c)(1), (2) Date Jul. 28, 2020,
PCT Pub. No. WO2019/184549, PCT Pub. Date Oct. 3, 2019.
Claims priority of application No. 201810263832.0 (CN), filed on Mar. 27, 2018.
Prior Publication US 2021/0122823 A1, Apr. 29, 2021
Int. Cl. C07K 16/28 (2006.01); C07K 16/32 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2809 (2013.01) [C07K 16/32 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/53 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/94 (2013.01)] 16 Claims
OG exemplary drawing
 
1. An antibody or antibody fragment, comprising an antigen binding domain that binds to CD3, wherein the antigen binding domain comprises a heavy chain variable domain (VH) having an amino acid sequence of SEQ ID NO: 21 and a light chain variable domain (VL) having an amino acid sequence of SEQ ID NO: 22.